Le Lézard
Classified in: Health, Science and technology, Business
Subject: CXP

Northway Biotech Opens New Biopharmaceutical Manufacturing Facility in Greater Boston Area


WALTHAM, Mass., Jan. 20, 2021 /CNW/ -- Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art, cGMP manufacturing site in Europe, announced at the virtual grand opening ceremony on Jan. 20, 2021, the opening of its new 30,000-square-foot process development and cGMP manufacturing site in Waltham, Massachusetts.

From cell line development to cGMP DS manufacturing and aseptic filling, the state-of-the-art facility, in the booming biotech hub in the Greater Boston area, will provide end-to-end services for biologics microbial and mammalian based biologics. Currently, the new site has fully established process, analytical method development, and quality control labs supporting local and international customer projects since summer 2020. The cGMP biomanufacturing suite will house 500 L microbial and 2,000 L mammalian bioreactors and be operational in Q4 2021, representing a capital investment program worth $40 million.

"Northway Biotech reaches an important strategic milestone to further strengthen its leadership by opening a second biomanufacturing facility and its first in the United States. We are very excited about this expansion and are poised to support our next-door partners in the Boston biotech hub, as well as other domestically or internationally located companies, by enabling accelerated development and manufacturing of their novel, life-saving biopharmaceuticals for clinical or commercial needs," said Dr. Vladas Algirdas Bumelis, CEO of Northway Biotech and Executive Chairman of the company's Board of Directors and Advisory Board.

Earlier last month, the company announced that it is changing its brand name from Northway Biotechpharma to Northway Biotech to harmonize its brand name across EU and U.S.-located sites.

About Northway Biotech - https://www.northwaybiotech.com

Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania; London, United Kingdom; and Waltham, Massachusetts, United States. 

For Further Information, Contact: 

Dr. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
[email protected]

Related Files

Northway Biotech opens new biopharmaceutical manufacturing facility in Greater Boston Area.pdf

Related Images

northway-biotech-opens-new.jpg
Northway Biotech opens new biopharmaceutical manufacturing facility in Greater Boston Area
Northway Biotech opens new biopharmaceutical manufacturing facility in Greater Boston Area

 

SOURCE Northway Biotech


These press releases may also interest you

at 01:49
Aker BP delivered continued strong operational performance in the first quarter of 2024, with low cost and low emissions, and with all field development projects progressing according to plan.  HighlightsIncreased production: Oil and gas production...

at 01:41
Solus Power, a leading innovator in electric vehicle (EV) charging solutions, has signed a Memorandum of Understanding (MOU) with global defence and security company, QinetiQ....

at 01:25
Well positioned for the gardening season First quarter 2024            Net sales decreased by 14% to SEK 14,719m (17,167). Changes in exchange rates had a neutral effect. Planned exits of low-margin petrol-powered business impacted with -4%. Organic...

at 01:24
Volvo Cars today reports an operating profit (EBIT) excluding joint ventures...

at 01:05
Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2024. Record net sales of 1.071 billion USD in the first quarter of 2024, surpassing for the first time the 1...

at 01:00
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. ? ?  Q1 2024? Q1 2023? % change? ?m? ?m? ActualCER1Growth...



News published on and distributed by: